The company raised more than $20 million after listing on the London Stock Exchange earlier this year.

Earlier this year, Cellular Goods, a cannabis skincare company backed by David Beckham, became just the third cannabis company to list on the London Stock Exchange (LSE).

The losses over the last year are attributed to the initial public offering (IPO) costs, investment into the business, which produces skincare products containing biosynthetic cannabinoids, and a £900,000 ($1.5 million) charge linked to “a share-based bonus scheme for management and staff.”

CBG, also known as the “mother cannabinoid,” contains potent antimicrobial and anti-inflammatory properties. A study out of McMaster University last year found the cannabinoid was capable of killing the superbug methicillin-resistant Staphylococcus aureus (MRSA).

The CBG not only destroyed the MRSA microbes, but also prevented the bacteria from forming “biofilms,” communities of microorganisms that attach to surfaces and allow them to spread.

According to the Evening Standard, Cellular Goods is now preparing a marketing push for early 2022.

In June, the company partnered with Vancouver-based Willow Biosciences Inc., a biotech company that develops and produces plant-derived ingredients for consumer care, food and beverages, and pharmaceutical products.

Under the terms of that multi-year agreement, Willow supplies Cellular Goods with its proprietary and biosynthetically produced CBG. The company produces cannabinoids without growing cannabis plants, but, instead, uses a yeast fermentation process.

“We’re still using a living organism to produce the cannabinoids, we’ve just adapted nature to our own needs,” CEO Trevor Peters told The GrowthOp earlier this year.

“These truly are health and wellness products that reduce inflammation, fight off bad microbes, even do things like pick up free radicals in our body and I think CBG can go a long way in that regard,” Peters said.